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Objective: Because of patients’ fear of surgery, the psychological symbolism of the 
male character, and significant encouragement by urologists, the majority of pa-
tients with advanced prostate cancer prefer medical castration as a choice of hor-
monal treatment. We investigated how the preserved testes were affected by 
medical castration with luteinizing hormone-releasing hormone (LH-RH) agonist 
and/or antiandrogen therapy.
Materials and Methods: Thirty-four consecutive patients with advanced prostate 
cancer who underwent a bilateral epididymal-sparing orchiectomy were enrolled in 
this study. Before surgery, 19 of them had received LH-RH agonists and/or antian-
drogens, while the other 15 patients had not. Morphological measurements were 
made immediately after the operation, and a histological examination was per-
formed by a uropathologist with confirmation by urologists. The axial length, weight, 
and histopathological findings of the testes and prostate-specific antigen (PSA)/tes-
tosterone level were compared between the two groups. Histological changes and 
characteristics were recorded and analyzed.
Results: The median axial length and weight of the testes in the 19 patients with 
prior medical castration were 2.6 (2.0–3.6) cm and 8.0 (6.0–11.5) g, which signifi-
cantly differed from those with primary surgical castration [4.0 (2.9–5.0) cm and 
12.0 (9.0–17.0) g, both p < 0.001]. Moreover, profound atrophic and fibrosclerotic 
changes were noted in the seminiferous tubules in the group with prior medical cas-
tration. Specific findings, including basement membrane thickening and interstitial 
cell hyperplasia, were noted in specimens with prior medical castration. However, 
the postoperative serum PSA and testosterone levels did not significantly differ be-
tween the two groups.
Conclusion: Medical castration in patients with advanced prostate cancer indeed 
caused a significant reduction in the volume and profound pathological change in 
the testes, which may compromise a patient’s expectation of his self-image (symbol 
of sexual virility).
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1.  Introduction
The mainstay treatment for advanced prostate cancer 
worldwide focuses on hormonal ablation with medical 
castration through luteinizing hormone-releasing hormone 
(LH-RH) agonists or surgical castration through bilateral 
orchiectomy, usually bilateral epididymal-sparing orchiec-
tomy. With the introduction of LH-RH agonists more 
than 20 years ago, medical castration has become a popular 
choice in hormonal therapy for advanced prostate cancer.1 
Medical castration seems to be preferred by patients with 
advanced prostate cancer due to concerns about the 
surgical risks and less-desirable cosmetic outcomes.1 The 
reasons for this phenomenon are multifactorial, and psy-
chological factors play important roles. Also, urologists tend 
to prescribe an LH-RH analog even though they still con-
sider the effects of this treatment modality conflicting.2 
Medical castration has somewhat replaced surgical cas-
tration and become the standard treatment for patients 
with advanced prostate cancer.
The majority of patients with advanced prostate cancer 
in Taiwan prefer medical castration as the choice of hor-
monal treatment due to the following factors: a patient’s 
fear of surgery, the psychological symbol of the male 
character, and significant encouragement by urologists. 
However, patients treated with an LH-RH analog may ex-
perience significant reduction in the size of the testicles, 
which may have a strong impact on the body self image 
of these patients. Potosky et al.3 even reported that pa-
tients who have undergone medical castration experi-
enced more bothersome symptoms with sexual 
function. In the past 2 years, some urologists in Taiwan 
have shifted their preferences from medical castration 
to surgical orchiectomy under financial pressures of the 
national global budget of the healthcare insurance sys-
tem. The same trend has also been observed in the US 
due to a decrease in reimbursement for medical andro-
gen ablation.4 We thus had a chance to investigate how 
the preserved testes are affected by medical castration 
using LH-RH agonists and/or antiandrogens.
2.  Methods
Thirty-four patients with pathologically proven prostatic 
cancer in the advanced stage were enrolled in this study. 
Hormonal therapy was indicated for all patients. Patients 
with a past history of scrotal trauma, mumps orchitis, or 
pelvic irradiation were excluded from this study. Among 
these patients, 19 had previously been treated with chem-
ical androgen deprivation therapy with either antiandrogen 
alone or total androgen blockade (the combination of LH-RH 
analogs and antiandrogen). The other 15 patients were 
hormonally naïve and underwent surgical castration as 
the primary hormonal therapy. The LH-RH analogs used in 
this study included Leuplin (Takeda Pharmaceutical Co. 
Ltd., Osaka, Japan), Zoladex (Astra Zeneca, London, UK), 
and Decapeptyl (Ferring GmbH, Kiel, Germany), and the 
antiandrogens included Androcur (Schering, France) and 
Fugeral (Schering-Plough, Canada). The indications for 
patients transferred from chemical castration to surgical 
castration included a rebound of prostate-specific antigen 
(PSA) level, inability to achieve a castration level of tes-
tosterone, and a request from the patient. Demographics 
and clinical information including biochemical tests were 
obtained through retrospective review of medical records.
Serum levels of PSA and total testosterone were 
measured preoperatively and 3 months postoperatively. 
The operative procedure for bilateral epididymal-sparing 
orchiectomy was performed through a small median 
raphe skin incision. Each testicle was dissected from its 
respective epididymis, the vessels ligated, and the testis 
removed. Epididymoplasty was then performed to re-
shape the epididymis into a spherical structure to simu-
late the appearance of a normal testis. All patients had 
a smooth postoperative course without complications. 
The axial length and weight of the testes were measured 
intraoperatively.
2.1. Histopathological examination
Specimens were placed in 10% formalin solution follow-
ing surgical excision and sent for gross and microscopic 
pathological analyses. The axial length and weight of 
each testis were recorded by operating urologists and 
rechecked by the examining pathologist. Testicular axial 
length and weight data were subsequently analyzed. A 
histopathological examination was conducted by a 
uropathologist (M.C.C. Lee). A grading system of the his-
topathological results of atrophic changes in the sem-
iniferous tubules was defined by the urologists and 
uropathologist (Figure 1). Four grades were classified ac-
cording to atrophic changes in the semi niferous tubules. 
Grade 0 was defined as a grossly normal seminiferous tu-
bule with adequate thickness of the spermatogenic cells 
with sperm production. Grade I was defined as decreased 
thickness of the spermatogenic cell layers and decreased 
sperm production by the seminiferous tubules. Grade II 
was defined as atrophic changes of the seminiferous tu-
bules with fewer than two layers of spermatogenic cells. 
Grade III was defined as marked atrophic changes in the 
seminiferous tubules with no visible spermatogenic cells. 
The pathological findings were recorded, and agreement 
was reached between the uropathologist and urologists. 
Any changes in the histopathological findings upon review 
were recorded and analyzed.
2.2.  Statistical analysis
Student’s t test was used for the statistical analysis of 
continuous variables and Fisher’s exact test for categori-
cal variables with statistical significance considered at 
p < 0.05. Statistical analysis was carried out with SPSS 
version 17.0 (SPSS Inc., Chicago, IL, USA).
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3.  Results
In total, 34 patients were recruited for this study. Among 
the patients, 19 underwent orchiectomy after hormonal 
therapy and 15 underwent orchiectomy as the primary 
hormonal therapy. We divided these patients into two 
groups: hormonal therapy group; hormonally naïve group. 
The results are shown in Table 1. The weight and axial 
length of the testes were significant higher in the hormo-
nally naïve group. The preoperative PSA and testoster-
one levels were significant higher in the hormonally naïve 
group. No difference was detected in the postoperative 
serum PSA or testosterone levels between the two groups.
The hormonal therapy group was further divided 
into antiandrogen (AA) and total androgen blockade (TAB) 
subgroups (Table 2). No significant difference was found 
A B C
Figure 1 (A) Grade I shows mild atrophic changes in the seminiferous tubules, including decreased thickness and sperm numbers. 
(B) Grade II shows prominent decreases in sperm and the thickness of the seminiferous tubules. (C) In grade III specimens, no viable 
sperm is found, and there is no active spermatogenesis.
Table 1 Demographics of the hormonal therapy group and the hormonally naïve group*
 Hormonal therapy group (n = 19) Hormonally naïve group (n = 15) p
Age (yr) 73 (62–81) 72 (68–78) 0.37
Testicle
  Axial length (cm) 2.6 (2.0–3.6) 4.0 (2.9–5.0) < 0.001
  Weight (g) 8.0 (6.2–11.5) 12.0 (9.0–17.0) < 0.001
PSA (ng/dL)
  Preoperative 21.6 (1.2–224.0) 128 (68.1–1072.0) 0.001
  Postoperative 17 (0.2–120.2) 12.1 (0.4–245.1) 0.32
Testosterone (ng/mL)
  Preoperative 0.8 (0.1–5.1) 3.1 (1.2–8.1) < 0.001
  Postoperative 0.1 (0.02–0.50) 0.14 (0.01–0.60) 0.22
*Data presented as mean (range). PSA = prostate-specific antigen.
Table 2 Comparison between antiandrogen alone and total androgen blockage subgroups*
 Antiandrogen alone (n = 7) Total androgen blockage (n = 12) p
Age (yr) 75 (62–80) 72.5 (65–81) 0.49
Duration (mo) 20 (8–40) 24 (7–46) 0.46
Testicle
  Axial length (cm) 2.6 (2.4–3.2) 2.7 (2.0–3.6) 0.24
  Weight (g) 8.1 (6.2–10.4) 8.3 (7.4–11.5) 0.12
PSA (ng/dL)
  Preoperative 21.2 (1.2–224) 21.3 (2.5–156.3) 0.35
  Postoperative 21.4 (0.8–54.3) 16.7 (0.8–120.2) 0.30
Testosterone (ng/mL)
  Preoperative 3.5 (1.0–5.1) 0.45 (0.1–1.20) < 0.001
  Postoperative 0.1 (0.03–0.20) 0.13 (0.02–0.50) 0.15
*Data presented as mean (range). PSA = prostate-specific antigen.
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in the parameters except for preoperative serum testoster-
one level, which was significantly higher in the AA group.
Histological examination showed marked atrophic 
changes in the seminiferous tubules in the hormonal 
therapy group. In contrast, healthy seminiferous tubules 
were found microscopically in the hormonally naïve group 
except in three specimens. A significant difference was 
found in atrophic grading between the hormonal therapy 
and hormonally naïve groups (Table 3). Two specific find-
ings were noted on reviewing the specimens: basement 
membrane thickening and interstitial cell hyperplasia. 
These findings are presented in Table 3. In the hormonal 
therapy group, an increased cell number was noted in the 
interstitial area, especially in the TAB group. Cells also 
showed hypertrophic changes (Figure 2). The original 
dominating cells in this area should be Leydig cells, and 
these hypertrophic cells were histologically similar to 
Leydig cells. The prevalence of this phenomenon was less 
in the AA subgroup compared to the TAB subgroup; how-
ever, there was no statistically significant difference 
(43% vs. 83%, p = 0.12). No such histological change was 
found in the hormonally naïve group. Basement membrane 
thickening was noted around the seminiferous tubules 
Table 3 Histological findings of the specimens
 
Histological atrophy
 Basement membrane Interstitial cell
  thickening hyperplasia
 Grade 0 Grade I Grade II Grade III No Yes No Yes
Group 1
  Antiandrogen 2/7 0/7 3/7 2/7 2/7 5/7 4/7 3/7
  Total blockade 2/12 2/12 2/12 6/12 2/12 10/12 7/12 5/14
Group 2 12/15 3/15 0/15 0/15 13/15 2/15 14/15 1/15
Figure 2 Hypertrophic and hyperplastic changes in interstitial 
cells (arrow) noted in some specimens with previous antiandrogen 
or total androgen blockade treatment.
Figure 3 In some specimens previously treated with antian-
drogen or total androgen blockade, the basement membrane 
was thickened and spermatogenesis was arrested.
and was usually associated with significant histological 
atrophic changes of the seminiferous tubules (Figure 3). 
The prevalence was higher in the hormone-treated group 
(79% vs. 13%, p = 0.0002). No trend of this phenomenon 
declining was detected in the TAB or AA group (83% vs. 
71%, p = 0.36).
4.  Discussion
Hormone-deprivation therapy is recognized as the stand-
ard approach for advanced or metastatic prostate cancer. 
Although the efficacy of chemical and surgical castration 
was reported to be comparable, surgical orchiectomy was 
somewhat abandoned after the development of chemical 
castration.5,6 The reasons for this phenomenon were mul-
tifactorial and included concerns about surgical risk and 
damage to one’s body image. Based on data from this 
study, the efficacies of surgical and medical castration 
were similarly reflected by the nadir testosterone level. 
Previous reports also showed similar results.1,5 Morbidity 
was also comparable between these two therapies, espe-
cially hormone-related symptoms, such as hot flushes, 
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weight gain, and sexual dysfunction. However, Potosky 
et al.3 reported that patients who receive medical cas-
tration experience more bothersome sexual dysfunction 
and worry about freedom from prostate cancer com-
pared to those who receive surgical castration.
Medical castration certainly causes testicular atrophy, 
which was more obvious than that produced by drug 
packet inserts (3.8–7.0%), but much less than that re-
ported by Issa et al. (50.3–53.3%).1 Furthermore, we re-
ported significant histopathological changes in this study. 
Profound atrophic changes in spermatogenesis were 
noted after chemical castration. The size and weight of the 
testicles were significantly lower in patients with prior 
chemical castration. A significant effect of chemical cas-
tration on the testicles was shown, and these results pos-
sibly eroded the body image of these patients. Although 
we did not investigate the quality of life index between 
the two treatment modalities, the results suggest an im-
pact of chemical castration on patients similar to that 
with surgical castration.
The cost-effectiveness of surgical castration is signifi-
cant, which may be beneficial to shortages in the global 
budget. The cost of medical castration surpasses surgical 
castration 2.7–5.3 months after initiating therapy depend-
ing on whether combined androgen blockade or LH-RH 
monotherapy is used. Mariani et al.7 reported that patients 
with short anticipated survival might experience a cost 
benefit with medical over surgical therapy; however, 
that population is small (5–6%). Bonzani et al.8 demon-
strated that the cost of medical castration far exceeded 
that of surgical castration in treating patients with advanced 
prostate cancer. A recent observational study showed 
decreased use of medical castration and an increase in 
surgical orchiectomy due to the decreased reimbursement 
for medical androgen ablation.4 Reimbursement is closely 
tied to the practice of urologists and may change the 
structure of medical costs. The potential economic effect 
of selecting surgical castration is significant in Taiwan. 
We estimated an average saving of 1.6 million New Taiwan 
dollars (у US$50,000) per patient based on the assumption 
of a 5-year life expectancy. Such savings would be a signifi-
cant portion of the total global budget for urology.
Surgical therapy is a simple and effective measure to 
achieve castration. It also eliminates the potential of poor 
compliance with medical therapy. In this study, there 
were no recognizable complications. Considering the pos-
sibility of misleading the patient, it is best for urologists to 
recommend that all patients be clearly informed about 
the low complication rate of an orchiectomy prior to de-
ciding on a choice of therapy. Because medical therapy 
with LH-RH agonists may have a less-desirable morbidity 
profile, a lower quality of life (related to damage to one’s 
self-image), worry about disease progression, and signifi-
cantly higher costs, a strong argument can be made to 
consider surgical therapy.3
Histological changes in specimens of patients with 
prior therapy showed many differences from those without 
previous chemical castration. Profound atrophic changes 
were noted in the seminiferous tubules. Various degrees 
of basement membrane thickening were also found. These 
findings suggested fibrosclerotic and atrophic changes 
due to the effect of chemical castration. In the interstitial 
area, there was an unexplained hyperplastic change in 
cells in about half of the specimens. We could not dif-
ferentiate the cell type, but they were possibly fibroblasts 
or Leydig cells. Previous reports showed that LH-RH ana-
logs may induce atrophy of Leydig cells in humans.9,10 
These interstitial hyper trophic cells need to be further 
investigated. In some patients, the resulting morphological 
changes due to chemical castration might differ from 
those of previous studies.
We developed a simple grading system for histopa-
thologically evaluating atrophic changes in orchiectomy 
specimens. Johnsen’s score was previously used to grade 
seminiferous changes of a testicular biopsy.11 Although 
this grading system is widely used to evaluate infertility, 
it is rarely used to evaluate testicular atrophic changes. 
In addition, the grading system is complicated, and we 
need a straightforward classification system. The system 
was developed by urologists and pathologists, and was 
developed according to findings of testicular atrophy 
caused by medication or aging. Although this system has 
not been validated, we think the system is reasonable 
and easy-to-use to classify atrophy of the seminiferous 
tubules.
This study has limitations. The case number of this 
study was small, and the study design was retrospective. 
The agents for chemical castration were not controlled. An 
uneven distribution of patients may have caused some 
bias. Although we noted hypertrophy and hyperplasia of 
cells in the interstitial area, we could not differentiate 
the cell types. Since the specimens were fixed with formalin, 
and hematoxylin and eosin staining was used, the enzyme 
activities of the cells could not be checked such as 3β-
hydrosteroid dehydrogenase. In addition, we did not fix 
the specimens in Bouin’s solution, since this method is 
not a routine fixation procedure in our institution. However, 
we still recognized significant pathological changes in 
patients with prior chemical castration.
Medical castration, which has merits of patient and 
physician preferences clinically and histopathologically, 
induces testicular atrophy. Damage to one’s body image 
can be induced in patients under both medical castration 
and surgical castration. Urologists should inform patients 
of the advantages and disadvantages of these two types 
of hormonal ablation before they make a decision, since 
post-medical testicular changes may compromise pa-
tients’ expectations (one’s symbol of sexual virility).
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